.Attributes Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a mean follow-up of 11 months, clients with metastatic stomach cysts who obtained biomarker-matched treatments based on distributing growth DNA profiling revealed a more significant professional benefit than those obtaining unequaled treatment.